Our
The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. Discussions include the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.
Biosimilars Review & Report (BR&R) provides education, commentary, and updates on the biosimilar marketplace. Visit https://biosimilarsrr.com/ for a frequently updated resource on the entire field, including biosimilar product profiles, an FDA approval and submissions database, and news on policy and coverage decisions. New articles are published regularly and may be accessed through visiting our website or via E-mail subscription.
Generics and Biosimilars Initiative (GaBI) was founded in 2008. GaBI aims to foster the worldwide efficient use of high quality and safe medicines at an affordable price, thus advancing and supporting the idea of accessible, affordable and sustainable health care.
The objective of GaBI is to raise the scientific status of generic and biosimilar medicines, via well-documented and up-to-date information about generic and biosimilar medicines both in print (www.gabi-journal.net) and electronically (www.gabionline.net) in an open access format, providing high quality, scientifically sound and reliable information to healthcare professionals including physicians, pharmacists and nurses, consumers, drug developers, third-party payers, legislators and assessors; who are in need of a reliable, critical and independent source of information on all aspects of generic and biosimilar medicines.
Subscribe to gain easy access of information on the latest scientific research and developments in generic and biosimilar medicines via GaBI Online to editorial@gabionline.net; or submit a manuscript to GaBI Journal to editorial@gabi-journal.net.
GaBI’s mission – Building trust in cost-effective treatments
Generics Bulletin from Informa Pharma Intelligence offers unrivalled coverage, news and analysis of the global generics, biosimilars and value-added medicines industries. This publication now delivers expanded Generics, Biosimilars and Value-Added Medicines content 24/7, with a new look, exciting new features and a customizable online platform to access the content on any internet or mobile device.
Informa Pharma Intelligence Awards 2022
The Global Generics and Biosimilars Awards celebrate the greatest achievements and innovations across the development, authorisation, marketing and distribution of global off-patent pharmaceuticals. Co-locating with CPhI Worldwide in Frankfurt, these illustrious awards provide a unique opportunity for the industry to come together to discuss future opportunities and challenges and shine a light on the companies and individuals driving positive change. Winners will be recognised across 14 categories, including Biosimilar Initiative of the Year, Leader of the Year, API Supplier of the Year and Business Development of the Year.
Pharma Intelligence is the leading provider of drug, device, company, clinical trial and market intelligence in the pharmaceutical and medtech markets. Our connected team of journalists, researchers and analysts are based in key markets around the globe. Drawing on a foundation of high-quality proprietary data you can trust that the insights gained through our solutions have the level of precision needed to make forward focused decisions with confidence.
Pharma Manufacturing is an Endeavor Business Media brand that serves the informational needs of pharma/biopharma professionals in manufacturing and operations, QA and QC, regulatory affairs, engineering and project management, packaging and corporate management. The brand provides in-depth coverage of the most pressing issues in the evolving pharma landscape and how industry thought leaders can tackle these challenges.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish
